Combination treatments with hydroxychloroquine and azithromycin are compatible with the therapeutic induction of anticancer immune responses.
Oncoimmunology
; 9(1): 1789284, 2020 07 08.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1066080
ABSTRACT
Amid controversial reports that COVID-19 can be treated with a combination of the antimalarial drug hydroxychloroquine (HCQ) and the antibiotic azithromycin (AZI), a clinical trial (ONCOCOVID, NCT04341207) was launched at Gustave Roussy Cancer Campus to investigate the utility of this combination therapy in cancer patients. In this preclinical study, we investigated whether the combination of HCQ+AZI would be compatible with the therapeutic induction of anticancer immune responses. For this, we used doses of HCQ and AZI that affect whole-body physiology (as indicated by a partial blockade in cardiac and hepatic autophagic flux for HCQ and a reduction in body weight for AZI), showing that their combined administration did not interfere with tumor growth control induced by the immunogenic cell death inducer oxaliplatin. Moreover, the HCQ+AZI combination did not affect the capacity of a curative regimen (cisplatin + crizotinib + PD-1 blockade) to eradicate established orthotopic lung cancers in mice. In conclusion, it appears that HCQ+AZI does not interfere with the therapeutic induction of therapeutic anticancer immune responses.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Protocolos de Quimioterapia Combinada Antineoplásica
/
Azitromicina
/
Tratamiento Farmacológico de COVID-19
/
Hidroxicloroquina
/
Neoplasias
Tipo de estudio:
Estudio pronóstico
/
Ensayo controlado aleatorizado
Tópicos:
Medicina tradicional
Límite:
Animales
/
Femenino
/
Humanos
País/Región como asunto:
Europa
Idioma:
Inglés
Revista:
Oncoimmunology
Año:
2020
Tipo del documento:
Artículo
País de afiliación:
2162402X.2020.1789284
Similares
MEDLINE
...
LILACS
LIS